Grant: Fellowship - Priority Announcement - Inflammatory Bowel Disease
University of Calgary
$45,000.00
Helminth parasites, regulatory macrophages and the control of enteric inflammation.
FY 2011-12
Summary
The onset of inflammatory bowel diseases (IBD) is a complex interaction amongst genetic and environmental factors. However these diseases share common mechanisms such as cytokine (TNF alpha, IL-1 beta, IL-12) and chemokine (CCL5) secretion patterns and recruitment of immune cell populations (neutrophils, macrophages, T cells) which can cause tissue damage. Hence, therapies are aimed either at dampening inflammatory cell influx or blocking pro-inflammatory cytokine secretion. An assessment of the immune response to parasitic helminths (worms) has revealed the presence of macrophages with both anti-inflammatory and tissue repairing abilities, termed alternatively activated macrophages (AAMs). The the use of this cell population arises as a novel therapeutic approach. However, mechanisms underlying AAM induction, efficacy and possible side-effects are poorly understood.
Extending from our earlier observation that AAMs can block chemically-induced colitis in mice, this project will add novel data on the induction and phenotype of helminth-induced AAMs, cytokine- induced AAMs and a regulatory macrophage (elicited by the consumption of cell debris). The ability and mechanism of action of these cells in the modulation of colitis in laboratory models will be compared. Ultimately we seek to better understand the AAM/regulatory macrophage as a cell with the potential to be used as an anti-inflammatory treatment for IBD.
Department
Program
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
243165
Name
Reyes Hernandez Jose L
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Janssen Inc. (North York, Ontario); Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Helminth parasites, regulatory macrophages and the control of enteric inflammation.
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Keyworddelim
Arginase; Colitis; Cytokines; Helminthic Parasites; Immune Regulation; Inflammation; Macrophages; Rna Expression; T Cells; Western Blot
Abstract
The onset of inflammatory bowel diseases (IBD) is a complex interaction amongst genetic and environmental factors. However these diseases share common mechanisms such as cytokine (TNF alpha, IL-1 beta, IL-12) and chemokine (CCL5) secretion patterns and recruitment of immune cell populations (neutrophils, macrophages, T cells) which can cause tissue damage. Hence, therapies are aimed either at dampening inflammatory cell influx or blocking pro-inflammatory cytokine secretion. An assessment of the immune response to parasitic helminths (worms) has revealed the presence of macrophages with both anti-inflammatory and tissue repairing abilities, termed alternatively activated macrophages (AAMs). The the use of this cell population arises as a novel therapeutic approach. However, mechanisms underlying AAM induction, efficacy and possible side-effects are poorly understood.
Extending from our earlier observation that AAMs can block chemically-induced colitis in mice, this project will add novel data on the induction and phenotype of helminth-induced AAMs, cytokine- induced AAMs and a regulatory macrophage (elicited by the consumption of cell debris). The ability and mechanism of action of these cells in the modulation of colitis in laboratory models will be compared. Ultimately we seek to better understand the AAM/regulatory macrophage as a cell with the potential to be used as an anti-inflammatory treatment for IBD.
Competitiondate
201110
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Reyes Hernandez, Jose L
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $45,000~ $0~